Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-502 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-502, CRTh2 antagonist; oral | DRUG | multiple dose, single schedule |
| Placebo; oral | DRUG | matching placebo |
Key Inclusion Criteria: * Documented history of bronchial asthma diagnosed at least 6 months prior to study start and prior to the age of 40 years. * Body mass index (BMI) of 18 to 35 inclusive. * An ACQ score of ≥ 1.5 at specified time points prior to first dose of study drug. * A best prebronchod...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
ARRY-502 is an investigational oral small molecule that was studied for the treatment of persistent asthma. It was evaluated in a Phase 2 clinical trial in adults with asthma. ARRY-502 is not approved for any indication and remains in clinical development.
ARRY-502 targets PTGDR2, also known as the CRTh2 receptor. It acts as an antagonist at this receptor. By blocking PTGDR2, ARRY-502 is designed to interfere with CRTh2-mediated signaling pathways involved in allergic inflammation, which is relevant to asthma.
ARRY-502 is being developed by Pfizer, Inc. (ticker: PFE). Pfizer is the company responsible for the clinical development of this oral CRTh2 antagonist for asthma.
ARRY-502 is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with persistent asthma. The drug is investigational and has not been approved by the FDA for any indication.
ARRY-502 has been studied in one completed Phase 2 clinical trial, NCT01561690, titled "A Study of ARRY-502 in Patients With Persistent Asthma." The trial enrolled 184 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, ARRY-502 is also known as a CRTh2 antagonist. CRTh2 is another name for the PTGDR2 receptor, which ARRY-502 targets. The terms ARRY-502 and CRTh2 antagonist refer to the same investigational compound.